Association between exposure to rotating night shift versus day shift using levels of 6-sulfatoxymelatonin and cortisol and other sex hormones in women

Chronobiology International

Volumn 32, Issue 1, 2015, Pages 128-135

  Gómez Acebo, Inés ^a,b,c   Dierssen Sotos, Trinidad ^a,b,c   Papantoniou, Kyriaki ^c,d,e,f   García Unzueta, María Teresa ^g   Santos Benito, María Francisca ^g   Llorca, Javier ^a,b,c  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b IDIVAL   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f UNIVERSITAT POMPEU FABRA   (Spain)

^g HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Breast cancer risk; Circadian disruption; Day shift work; Light exposure; Rotating night shift work

Indexed keywords

6-SULFATOXYMELATONIN; BIOLOGICAL MARKER; HYDROCORTISONE; MELATONIN; SEX HORMONE;

ADULT; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; BLOOD; CIRCADIAN RHYTHM; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MIDDLE AGED; PATHOPHYSIOLOGY; PERSONNEL MANAGEMENT; SLEEP DISORDER; SPAIN; TIME; URINE; WORK; WORKLOAD; YOUNG ADULT;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CHRONOBIOLOGY DISORDERS; CIRCADIAN RHYTHM; CROSS-SECTIONAL STUDIES; FEMALE; GONADAL STEROID HORMONES; HUMANS; HYDROCORTISONE; JOB DESCRIPTION; MELATONIN; MIDDLE AGED; PERSONNEL STAFFING AND SCHEDULING; SPAIN; TIME FACTORS; WORKLOAD; YOUNG ADULT;

EID: 84921768824     PISSN: 07420528     EISSN: 15256073     Source Type: Journal    
DOI: 10.3109/07420528.2014.958494     Document Type: Article

References (40)

1. Barakat RR. (1997). Benign and hyperplastic endometrial changes associated with tamoxifen use. Oncology (Williston Park). 11:35-7.
2. Brinton LA, Berman ML, Mortel R, et al. (1992). Reproductive, menstrual, and medical risk factors for endometrial cancer: Results from a case-control study. Am J Obstet Gynecol. 167:1317-25.
3. Brzezinski A. (1997). Melatonin in humans. N Engl J Med. 336:186-95.
4. Costa G, Haus E, Stevens R. (2010). Shift work and cancer - Considerations on rationale, mechanisms, and epidemiology. Scand J Work Environ Health. 36:163-79.
5. Cummings SR, Eckert S, Krueger KA, et al. (1999). The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA. 281:2189-97.
6. Early Breast Cancer Trialists' Collaborative Group. (1998). Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet. 351:1451-67.
7. Erowid (2-2-2011). Caffeine content of beverages, foods, & medications. Available from: http://www.erowid.org/chemicals/caffeine/ caffeine-info1.shtml [last accessed 16 Jul 2014].
8. Fisher B, Powles TJ, Pritchard KJ. (2000). Tamoxifen for the prevention of breast cancer. Eur J Cancer. 36:142-50.
9. Fritschi L, Erren TC, Glass DC, et al. (2013). The association between different night shiftwork factors and breast cancer: A case-control study. Br J Cancer. 109:2472-80.
10. Fu Z, Inaba M, Noguchi T, Kato H. (2002). Molecular cloning and circadian regulation of cryptochrome genes in Japanese quail (Coturnix coturnix japonica). J Biol Rhythms. 17:14-27.
11. Graham C, Cook MR, Gerkovich MM, Sastre A. (2001). Examination of the melatonin hypothesis in women exposed at night to EMF or bright light. Environ Health Perspect. 109:501-7.
12. Graham C, Cook MR, Kavet R, et al. (1998). Prediction of nocturnal plasma melatonin from morning urinary measures. J Pineal Res. 24:230-8.
13. Grundy A, Richardson H, Burstyn I, et al. (2013). Increased risk of breast cancer associated with long-term shift work in Canada. Occup Environ Med. 70:831-8.
14. Hansen J, Stevens RG. (2012). Case-control study of shift-work and breast cancer risk in Danish nurses: Impact of shift systems. Eur J Cancer. 48:1722-9.
15. Haus EL, Smolensky MH. (2013). Shift work and cancer risk: Potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Med Rev. 17:273-84.
16. Henderson BE, Feigelson HS. (2000). Hormonal carcinogenesis. Carcinogenesis. 21:427-33.
17. IARC Group 2A. (2010). IARC monographs on the evaluation of carcinogenic risks to humans. Painting, Firefighting, and shift-work. IARC Monogr Eval Carcinog. Risks Hum. 98:570-818.
18. Ijaz S, Verbeek J, Seidler A, et al. (2013). Night-shift work and breast cancer-A systematic review and meta-analysis. Scand J Work Environ Health. 39:431-47.
19. Jia Y, Lu Y, Wu K, et al. (2013). Does night work increase the risk of breast cancer? A systematic review and meta-analysis of epidemiological studies. Cancer Epidemiol. 37:197-206.
20. Kaaks R, Rinaldi S, Key TJ, et al. (2005). Postmenopausal serum androgens, oestrogens and breast cancer risk: The European prospective investigation into cancer and nutrition. Endocr Relat Cancer. 12:1071-82.
21. Key T, Appleby P, Barnes I, Reeves G. (2002). Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst. 94:606-16.
22. Langley AR, Graham CH, Grundy AL, et al. (2012). A cross-sectional study of breast cancer biomarkers among shift working nurses. BMJ Open. 2:e000532.
23. Leon-Blanco MM, Guerrero JM, Reiter RJ, et al. (2003). Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J Pineal Res. 35:204-11.
24. Mirick DK, Davis S. (2008). Melatonin as a biomarker of circadian dysregulation. Cancer Epidemiol Biomarkers Prev. 17:3306-13.
25. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. (2004). Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 96:1856-65.
26. Nagata C, Nagao Y, Yamamoto S, et al. (2008). Light exposure at night, urinary 6-sulfatoxymelatonin, and serum estrogens and androgens in postmenopausal Japanese women. Cancer Epidemiol Biomarkers Prev. 17:1418-23.
27. Nelson W, Tong YL, Lee JK, Halberg F. (1979). Methods for cosinor-rhythmometry. Chronobiologia. 6:305-23.
28. Papantoniou K, Pozo OJ, Espinosa A, et al. (2014). Circadian variation of melatonin, light exposure, and diurnal preference in day and night shift workers of both sexes. Cancer Epidemiol Biomarkers Prev. 23:1176-86.
29. Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. Chronobiol Int. 27:1911-29.
30. Reiter RJ. (1980). The pineal and its hormones in the control of reproduction in mammals. Endocr Rev. 1:109-31.
31. Reiter RJ, Tan DX, Jou MJ, et al. (2008). Biogenic amines in the reduction of oxidative stress: Melatonin and its metabolites. Neuro Endocrinol Lett. 29:391-8.
32. Schernhammer ES, Berrino F, Krogh V, et al. (2010). Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: The ORDET cohort. Cancer Epidemiol Biomarkers Prev. 19:729-37.
33. Schernhammer ES, Hankinson SE. (2009). Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. Cancer Epidemiol Biomarkers Prev. 18:74-9.
34. Schernhammer ES, Kroenke CH, Laden F, Hankinson SE. (2006). Night work and risk of breast cancer. Epidemiology. 17:108-11.
35. Schernhammer ES, Rosner B, Willett WC, et al. (2004). Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomarkers Prev. 13:936-43.
36. Stevens RG, Blask DE, Brainard GC, et al. (2007). Meeting report: The role of environmental lighting and circadian disruption in cancer and other diseases. Environ Health Perspect. 115:1357-62.
37. Stevens RG, Rea MS. (2001). Light in the built environment: Potential role of circadian disruption in endocrine disruption and breast cancer. Cancer Causes Control. 12:279-87.
38. Straif K, Baan R, Grosse Y, et al. (2007). Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 8:1065-6.
39. Travis RC, Allen DS, Fentiman IS, Key TJ. (2004). Melatonin and breast cancer: A prospective study. J Natl Cancer Inst. 96:475-82.
40. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, et al. (2004). Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: Long-term results of a prospective study. Br J Cancer. 90:153-9.